115450 — HLB Therapeutics Co Income Statement
0.000.00%
Last trade - 00:00- KR₩257bn
- KR₩288bn
- KR₩55bn
- 41
- 20
- 12
- 10
Annual income statement for HLB Therapeutics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 42,930 | 43,586 | 42,403 | 52,591 | 54,932 |
| Cost of Revenue | |||||
| Gross Profit | 6,578 | 5,133 | 8,819 | 7,359 | 10,201 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 55,316 | 59,955 | 50,349 | 60,629 | 70,594 |
| Operating Profit | -12,386 | -16,368 | -7,946 | -8,038 | -15,662 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17,401 | -17,764 | -11,573 | -2,965 | -22,926 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17,401 | -17,764 | -11,573 | -2,965 | -22,926 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -16,902 | -17,197 | -11,354 | -2,302 | -22,793 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16,902 | -17,197 | -11,354 | -2,302 | -22,793 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -276 | -194 | -149 | -37 | -171 |
| Dividends per Share |